Journal of Life Science (생명과학회지)

Korean Society of Life Science (한국생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Inhibitors on the Function and Activity of Topoisomerase, and Gene Expression in HL-60 Human Leukemia Cells

HL-60 세포의 유전자 발현 및 topoisomerase의 기능 활성에 미치는 억제제의 영향

  • Jeong, In-Cheol (Department of Biochemistry, Kosin University College of Medicine) ;
  • Cho, Moo-Youn (Department of Biochemistry, Kosin University College of Medicine) ;
  • Park, Jang-Su (Department of Chemistry, College of Natural Science, Pusan National University)
  • 정인철 (고신대학교 의과대학 생화학 교실) ;
  • 조무연 (고신대학교 의과대학 생화학 교실) ;
  • 박장수 (부산대학교 자연과학대학 화학과)
  • Published : 2008.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

This studies were designed to elucidate whether inhibitors of topoisomerase regulate function and activity of topoisomerase, and gene expression in HL-60 human leukemia cells. HL-60 cells were treated with 10-hydroxycamptothecin or doxorubicin, total RNA was isolated, and expressed genes were investigated with human oligonucleotide microarray containing 10K gene, respectively. Expression profiles of the human leukemia HL-60 cells treated with 10-hydroxycamptothecin (10-CIT) or doxorubicin associated with signal transduction,. cell adhesion, cell cycle, cell growth, cell proliferation, cell differentiation, transcription and immune response, especially genes related with transcription and cell growth. In HL-60 cells treated with 10-CPT, the expression of topoisomerase III${\alpha}$, III${\beta}$ and I gene from oligo chip microarray analysis were increased over, but the expression of topoisomerase II${\alpha}$ and II${\beta}$ gene were decreased over. In contrast, the expression of topoisomerase II${\alpha}$ and II${\beta}$ gene were increased over in HL-60 cells treated with doxorubicin, whereas the expression of topoisomerase III${\alpha}$ and III${\beta}$ mRNA remained no significant change. These results suggest that these data may be useful for novel therapeutic markers.

인체 DNA topoisomerase는 DNA를 단일 또는 두 가닥을 일시적인 절단을 촉매하여 DNA의 topological 문제를 조절함으로써, DNA 복제, 전사, 재조합과 유사분열 과정 등에 관여한다. 이 효소는 많은 항생, 항암제의 표적효소로서 널리 알려져 있으며, 이들 유도체를 이용한 다양한 억제제의 개발과 임상적 응용에 관한 연구가 활발하게 진행되고 있다. 본 실험에서는 인체 백혈병 HL-60 세포에서 topoisomerase 억제제가 topoisomerase 기능 활성과 유전자 발현을 조절하는지를 규명하기 위하여 본 연구를 수행하였다. 연구 방법은 HL-60세포에 topoisomerase type I과 type II의 대표적 억제제인 10-hydroxycamptothecin (10-CPT)과 doxorubicin을 투여한 후 total RNA를 분리하였고, 10K-oligo-nucleotide microarray 방법으로 분석하여 유전자의 발현 양상을 조사하였다. 연구 결과에 의하면 10-CPT 또는 doxorubicin을 투여한 HL-60세포에서의 유전자 발현 양상은 주로 signal transduction, cell adhesion, cell cycle, cell growth, cell proliferation, cell differentiation, transcription 및 immune response 등과 관련이 있었다. Topoisomerase type I의 억제제인 10-CPT를 HL-60 세포주에 투여 하였을 때 type I으로 분류되는 topoisomerase III${\alpha}$, III${\beta}$ 및 I의 발현은 증가하였으나 type II인 topoisomerase II${\alpha}$와 II${\beta}$의 유전자의 발현은 감소되었다. 반대로 type II의 억제제인 doxorubicin을 투여하였을 때는 앞의 결과와 상반된 topoisomerase II${\alpha}$와 II${\beta}$의 유전자의 발현이 현저히 증가되었으며, topoisomerase III${\alpha}$와 III${\beta}$의 mRNA의 발현은 약간 감소하는 양상을 보였으나 의미 있는 차이는 없었다. 이 연구 결과는 앞으로 항암제의 기전을 밝히고 약물에 대한 치료 반응을 예측하고 새로운 약제 개발에 기초자료가 될 것으로 여겨진다.

Keywords

References

  1. Champoux, J.J. 2001. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70, 369-413. https://doi.org/10.1146/annurev.biochem.70.1.369
  2. Chen, S., S. P. Gomez, D. McCarley and M. G. Mainwaring. 2002. Topotecan-induced topoisomerase II alpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Cancer Chemother. Pharmacol. 49, 347-355. https://doi.org/10.1007/s00280-002-0423-9
  3. Cho, M. Y. and J. C. Jeong. 2004. Effects of doxorubicin on the activity and expression of topoisomerase in HL-60 human leukemia cells. Kosin Medical J. 19, 286-293.
  4. Christman, M. F., F. S. Dietrich and G. R. Frink. 1988. Mitotic recombination in the rRNA of S.cerevisiae is suppressed by the combined action of to po I and II. Cell 55, 413-425. https://doi.org/10.1016/0092-8674(88)90027-X
  5. Clary, A, A. Larrue, P. Pourquier and J. Robert. 1998. Transcriptional down- regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine. Anticancer Drugs 9, 245-254. https://doi.org/10.1097/00001813-199803000-00007
  6. Fornari, F. A., D. W. Jarvis, S. Grant, M. S. Orr, J. K. Randolph, F. K. White and D. A. Gewirtzm. 1996. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem. Pharmacol. 51, 931-940. https://doi.org/10.1016/0006-2952(96)00050-0
  7. Guo, X., J. Zhang, X. Fu, Q. Wei, Y. Lu, Y. Li, G. Yin, Y. Mao, Y. Xie, Y. Rui and K. Ying. 2006. Analysis of common gene expression patterns in four human tumor cell lines exposed to amptothecin using cDNA microarray: identification of topoisomerase-mediated DNA damage response pathways. Front Biosci. 1, 1924-1931.
  8. Jain, P. T., F. A. Fornari, J. K. Randolph, M. S. Orr and D. A 1998. Gewirtz. Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells. Biochem. Pharmacol. 55, 1263-1269. https://doi.org/10.1016/S0006-2952(97)00618-7
  9. Jeong, I. C. and M. Y. Cho. 2006. Analysis of gene expression profile in 10-hydroxycamptothecin-treated human leukemia HL-60 cells using oligonucleotide microarray. Kosin Medical J. 21, 338-343.
  10. Jeong, J. C. and M. Y. Cho. 2006. Effects of irinotecan on the activity and expression of topoisomerase I and III in HL-60 human leukemia cells. Kosin Medical J. 21, 344-348.
  11. Jeong, I. C., D. S. Jung, K. J. Ryu, J. S. Park and M. Y. Cho. 2000. Effects of camptothecin on the expression of DNA topoisomerase I and c-myc in HL-60 human leukemia cells. J. Life Sci. 10, 621-629.
  12. Jeong, I. C., N. J. Lee, S. U. Lee, S. J. Lee and M. Y. Cho. 2004. Expression profile of topoisomerase, ras and myc genes in HL-60 cells treated with camptothecin. Kosin Medical J. 19, 271-278.
  13. John, M., A. Diego, S. Qiuhu, J. W. Andrew, A. C. Georgia, N. Courtney, J. A. Maria, L. Martin, L. S. Edward and H. A. Leonard. 2003. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 63, 8791-8812.
  14. Kazuya, K., R. Manasi, R. Roald, G. E. Abdel, L. B. Michael, S. M. Paul, M. T. Jeffrey, S. D. William and V. C. Khew, 2000. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60, 4161-4166.
  15. Kersting, G., M. V. Tzvetkov, K. Huse, B. Kulle, V. Hafner, J. Brockmoller and L. Wojnowski. 2006. Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells. Naunyn Schmiedebergs Arch. Pharmacol. 374, 21-30. https://doi.org/10.1007/s00210-006-0091-0
  16. Liu, L. F. 1989. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58, 351-375. https://doi.org/10.1146/annurev.bi.58.070189.002031
  17. Nair, J., F. Traganos and Y. C. Tse-Dinh. 2000. Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines. Anticancer Res. 20, 4183-4188.
  18. Orr, M. S., F. A. Fornari, J. K. Randolph and D. A. Gewirtz. 1995. Transcriptional down-regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase II inhibitor, VM-26. Biochim. Biophys. Acta. 1262, 139-145. https://doi.org/10.1016/0167-4781(95)00064-N
  19. Perego, P., G. Capranico, R. Supino and F. Zunino. 1994. Topoisomerase I gene expression and cell sensitivity to camptothecin in human cel1 lines of different tumor types. Anticancer Drugs 5, 645-649. https://doi.org/10.1097/00001813-199412000-00006
  20. Pu, Q. Q. and W. R. Bezwoda. 1999. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function. Mol. Pharmacol. 56, 147-153. https://doi.org/10.1124/mol.56.1.147
  21. Sandri, M. I., D. Hochhauser, P. Ayton, R. C. Camplejohn, R. Whitehouse, H. Turley, K. Gatter, I. D. Hickson and A. L. Harris, 1996. Differential expression of the topoisomerase II alpha and beta. Br. J. Cancer 73, 1518-1524. https://doi.org/10.1038/bjc.1996.286
  22. Schomburg, U. and F. Grosse. 1986. Purification and characterization of DNA topoisomerase II from calf thymus associated with polypeptides of 175 and 150 kDa. Eur. J. Biochem. 160, 451-457. https://doi.org/10.1111/j.1432-1033.1986.tb10061.x
  23. Stahl, M., S. Kasimir-Bauer and A. Harstrick. 1997. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro. genes in human breast cancers. Anticancer Drugs 8, 671-676. https://doi.org/10.1097/00001813-199708000-00005
  24. Thielmann, H. W. and O. Popanda. 1998. Doxorubicin and gamma rays increase the level of DNA topoisomerase II alpha in nuclei of normal and xeroderma pigmentosum fibroblasts. J. Cancer Res. Clin. Oncol. 124, 355-366. https://doi.org/10.1007/s004320050184
  25. Wall, M. E., M. C. Wani, C. E. Cook, K. H. Palmer, A. T. McPhail and G. A. Sim. 1966. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor. J. Am. Chem. Soc. 88, 3888-3890. https://doi.org/10.1021/ja00968a057
  26. Wang, J. C. 1985. DNA topoisomerases, Annu. Rev. Biochem. 54, 665-697. https://doi.org/10.1146/annurev.bi.54.070185.003313
  27. Wang, J. C. 1987. Recent studies of DNA topoisomerases. Biochim. Biophys. Acta. 909, 1-9. https://doi.org/10.1016/0167-4781(87)90040-6
  28. Wang, J, J. Medeiros, D. L. Longo, A. Mansoor, M. Raffeld, P. I. Duffey, E. S. Jaffe and M. S. Stevenson. 1996. Use of the polymerase chain reaction technique to determine c-myc expression in follicular center cell lymphoma. Diagnostic Mol. Pathol. 5, 20-25. https://doi.org/10.1097/00019606-199603000-00004
  29. Xu, J. M., A. Azzariti, S. Tommasi, R. Lacalamita, G. Colucci, P. G. Johnston, S. W. Church and A. Paradiso. 2002. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. Clin. Colorectal Cancer 2, 182-188. https://doi.org/10.3816/CCC.2002.n.023
  30. Zhou, Y., F. G. Gwadry, W. C. Reinhold, L. D. Miller, L. H. Smith, U. Scherf, E. T. Liu, K. W. Kohn, Y. Pommier and J. N. Weinstein. 2002. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res. 62, 1688-1695.